Forest Laboratories (FRX) to acquire Clinical Data (CLDA) for $30/share in cash and another...

|About: Forest Laboratories, Inc. (FRX)|By:, SA News Editor

Forest Laboratories (FRX) to acquire Clinical Data (CLDA) for $30/share in cash and another $6/share on milestones. The $1.2B deal is a 6.6% premium to the average share price since CLDA announced FDA approval of its major depressive disorder treatment Viibryd, which sent shares up more than 50%. (PR)